Please login to the form below

Not currently logged in
Email:
Password:

Redx Pharma appoints new chief medical officer

Dr Andrew Saunders joins the UK biotech from Lytix Biopharma

Dr Andrew SaundersDrug discovery and development group Redx Pharma has appointed Dr Andrew Saunders as its chief medical officer (CMO), a role that will see him work with the R&D team fronting the clinical development of the company’s lead candidate.

Dr Saunders has worked in the oncology field for over 25 years and has experience in all aspects of the clinical development of oncology drugs.

He joins the UK biotech from Lytix Biopharma, a Norweigan immuno-oncology biotech, where he also served as CMO.

During his career, Dr Saunders has held several roles for both pharma and biotech companies, including Genzyme - now part of Sanofi, Roche, and Eli Lilly.

Ian Ross, chairman of Redx Pharma, said: “Dr Saunders brings a wealth of relevant experience and expertise in the clinical development of oncology drugs, which will be invaluable as the company transforms into a clinical stage company with the anticipated commencement of the first phase I study on lead compound RXC004.”

25th January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics